Butterfly Network (BFLY) Q2 2023: Enterprise Software ARR Jumps 58% as Cost Resets Drive Margin Upside
Enterprise software momentum and a leaner cost base mark a pivotal quarter for Butterfly Network, as the company’s U.S. business and recurring software revenue offset international headwinds. Leadership’s focus on core strengths, a streamlined commercial strategy, and a next-gen product pipeline signal a reset for sustainable growth, while conservative guidance reflects near-term transition risk. Investors should watch for execution on new product launches and international recovery as the company pivots from cost-cutting to growth initiatives.
Summary
- Enterprise Software Mix Expands: Recurring software revenue drives margin gains and anchors growth strategy.
- Cost Structure Realignment: Operating expense reductions extend runway and sharpen commercial focus.
- Product Roadmap Inflection: IQ3 launch and Butterfly Garden ecosystem position the company for renewed growth in 2024.
Business Overview
Butterfly Network develops and commercializes point-of-care ultrasound (POCUS) devices powered by proprietary ultrasound-on-chip technology, enabling clinicians to perform imaging with a single, portable probe across multiple care settings. The company generates revenue from hardware sales, recurring software subscriptions, services, and education, with major segments including U.S. healthcare, international markets, and veterinary (VET). Software and services are increasingly central to the business model, supporting both direct and distributor sales channels.
Performance Analysis
Butterfly’s Q2 results reflected a business in transition, with total revenue slightly down year-over-year due to international and VET segment declines, but U.S. sales up 21% on robust medical school and enterprise software deals. Enterprise software annual recurring revenue (ARR) surged 58%, now representing 35% of total ARR, highlighting successful penetration into hospital systems and a shift towards higher-margin, recurring revenue streams.
Gross margin improved to 59%, up from 55% last year, as software and services mix expanded and manufacturing efficiencies took hold. Adjusted EBITDA loss narrowed significantly, reflecting a $2 million per month reduction in operating expenses following a major reorganization. While international revenue fell 44% due to distributor inventory overhang and lapping of large prior-year deals, management emphasized this as a temporary setback with new leadership and pipeline development underway.
- U.S. Commercial Execution: Two large medical school deployments and higher subscription revenue drove domestic growth.
- International Inventory Drag: Distributor sell-through lagged, delaying replenishment orders and segment recovery.
- Software Mix Shift: Software and services now comprise 34% of revenue, up 3.5 points YoY, bolstering margin resilience.
Overall, the quarter marks a turning point, with Butterfly resetting its revenue baseline and cost structure while preparing for a new phase of product-driven growth.
Executive Commentary
"We ensured our new strategy is matched with the right cost structure to deliver on it. We implemented growth initiatives for all phases of our business and have a revenue growth plan that will be powered by better execution and near-term product pipeline that will roll out over the next several quarters."
Joe, Chief Executive Officer
"This process culminated in a more specific tactical roadmap and plan for reorganization that will allow us to further extend our cash and reinvest in our direct sales team. This exercise is expected to reduce our ongoing operating expense by an average of $2 million per month or about $60 million through the end of 2025."
Heather Goetz, Chief Financial and Operations Officer
Strategic Positioning
1. U.S. Market Focus and Commercial Realignment
Leadership is doubling down on U.S. healthcare, where demand for POCUS solutions and software integration remains strong. The company increased direct sales territories by 50% and launched a new partnership with McKesson, aiming to expand market share through focused commercial investment and execution.
2. Enterprise Software and Recurring Revenue
Enterprise software has become a core growth engine, with hospital deals driving 58% ARR growth and expanding the installed base. This recurring revenue stream supports margin expansion and customer stickiness, while new software features and modules are set to deepen wallet share and cross-sell opportunities.
3. Next-Gen Product Pipeline: IQ3 and Butterfly Garden
The pending launch of IQ3, Butterfly’s third-generation probe, is positioned to close the imaging quality gap, expand use cases, and enable automatic image capture, targeting both existing and new customers. Butterfly Garden, the new developer ecosystem, opens the platform to third-party AI and software partners, monetizing the ultrasound-on-chip IP and broadening the addressable market.
4. International Turnaround Initiatives
While international performance lagged, new sales leadership and a market-by-market focus are in place to rebuild distributor momentum and pipeline. Underlying sell-through is improving, but inventory normalization will take time before growth resumes.
5. Platform Leverage and Embedded Technology
Management is exploring partnerships to embed Butterfly’s MEMS chip in implantables, endoscopic, and other medical devices, seeking to monetize R&D investment and extend the technology’s reach beyond the company’s own channels.
Key Considerations
The quarter’s results underscore Butterfly’s pivot from broad ambition to disciplined execution, with a renewed emphasis on core strengths, recurring revenue, and operational efficiency. The company is now positioned to capitalize on its technology lead and commercial reset, but must deliver on pipeline execution and international recovery to regain growth momentum.
Key Considerations:
- Enterprise Software Momentum: Sustained ARR growth is vital for margin expansion and valuation rerating.
- Execution on IQ3 Launch: Timely regulatory approval and effective upgrade incentives will determine adoption and revenue impact.
- International Recovery Pace: Distributor sell-through and new leadership must translate into renewed order flow.
- Cost Discipline vs. Growth Investment: Balancing lean operations with targeted sales and R&D spend is critical for sustainable growth.
- Platform Monetization: Success of Butterfly Garden and embedded chip partnerships could unlock new revenue streams and competitive moats.
Risks
Butterfly faces near-term risks from delayed international orders, customer purchase deferrals ahead of IQ3 launch (the Osborne effect), and the challenge of scaling enterprise software in a competitive hospital environment. Execution risk remains elevated as the company integrates cost cuts with new growth initiatives, and regulatory delays for IQ3 could further pressure revenue. Analysts pressed management on the timing and predictability of large deals, highlighting the need for more consistent, repeatable revenue streams.
Forward Outlook
For Q3 and the remainder of 2023, Butterfly guided to:
- Full-year 2023 revenue of at least $64 million, reflecting a reset baseline and no large one-time deals in the forecast.
- Adjusted EBITDA loss of $80 to $75 million, an improvement of $10 to $15 million versus prior guidance.
Management highlighted several factors that shape the outlook:
- International order timing and IQ3-related purchase delays may weigh on near-term sales.
- Upside potential exists from new product launches, expanded direct sales, and Butterfly Garden partnerships not yet in the baseline.
Takeaways
Butterfly’s reset quarter signals a shift from cost containment to focused growth, with a clear path to margin improvement and product-driven expansion.
- Enterprise Software as a Growth Anchor: Recurring revenue and hospital adoption are now core to the business model, supporting sustainable margin gains.
- Operational Discipline Yields Runway: Cost reductions have extended cash runway, but management must now execute on commercial and product initiatives to reignite top-line growth.
- Execution on IQ3 and Platform Monetization: The success of next-gen launches and ecosystem partnerships will determine Butterfly’s ability to transition from stabilization to leadership in the POCUS market.
Conclusion
Butterfly Network’s Q2 marked a necessary inflection, as the company realigned around software, margin, and disciplined execution. With a leaner organization, clear commercial priorities, and a robust product pipeline, Butterfly is positioned for a return to organic growth—provided it delivers on key launches and international recovery in the coming quarters.
Industry Read-Through
Butterfly’s pivot underscores a broader industry trend toward recurring software revenue and platform ecosystems in medtech, as hardware commoditization pressures margins and customer stickiness. Enterprise software adoption in hospitals and bundled device-software solutions are becoming critical for differentiation and margin expansion. The Butterfly Garden initiative signals growing demand for open, developer-friendly platforms in digital health, with implications for medtech incumbents and new entrants alike. International distributor inventory dynamics and the Osborne effect are cautionary signals for peers launching next-gen devices, highlighting the importance of upgrade paths and clear segmentation strategies.